AtriCure (NASDAQ:ATRC) Issues Earnings Results

AtriCure (NASDAQ:ATRC) released its quarterly earnings results on Thursday. The medical device company reported $0.18 EPS for the quarter, FiscalAI reports. AtriCure had a return on equity of 2.37% and a net margin of 1.85%.The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same period in the prior year, the firm earned ($0.13) earnings per share. AtriCure updated its FY 2026 guidance to 0.240-0.320 EPS.

Here are the key takeaways from AtriCure’s conference call:

• AtriCure reported Q2 revenue of $154 million, up 13% year over year, with U.S. revenue growth of 14% driven by strong adoption across pain management, appendage management, and open ablation.
• Profitability improved sharply, with adjusted EBITDA of $27.3 million and net income of $9 million; management also raised full-year 2026 adjusted EBITDA guidance to $85 million-$89 million.
• The BoxX-NoAF trial is ahead of schedule, having surpassed 50% enrollment and more than 500 patients, with full enrollment still expected by year-end and data readouts targeted for the first half of 2027.
• Pain management was a standout, growing 27% worldwide on CryoSphere MAX adoption, while CryoXT is still early but expected to contribute more meaningfully in the second half of the year.
• Management acknowledged continued pressure in minimally invasive ablation and some international markets, especially the U.K. and Germany, while noting new competition in appendage management could create near-term trialing but is not expected to derail the business.

AtriCure Stock Up 6.2%

ATRC opened at $35.04 on Friday. The stock has a market capitalization of $1.77 billion, a P/E ratio of 166.87 and a beta of 1.24. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. AtriCure has a one year low of $25.36 and a one year high of $43.18. The business’s 50-day simple moving average is $30.05 and its 200-day simple moving average is $31.42.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 3,000 shares of AtriCure stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the transaction, the director directly owned 26,373 shares of the company’s stock, valued at $755,586.45. The trade was a 10.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Several institutional investors have recently added to or reduced their stakes in ATRC. Geneos Wealth Management Inc. purchased a new stake in AtriCure during the 2nd quarter valued at approximately $37,000. Smartleaf Asset Management LLC grew its stake in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the last quarter. State of Wyoming acquired a new position in shares of AtriCure in the fourth quarter valued at approximately $75,000. Kemnay Advisory Services Inc. acquired a new position in shares of AtriCure in the fourth quarter valued at approximately $114,000. Finally, Strs Ohio purchased a new stake in shares of AtriCure during the first quarter worth approximately $158,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure News Summary

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Q2 earnings of $0.18 per share beat the $0.03 consensus and improved from a loss a year ago, showing a meaningful profitability turnaround. AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue of $153.6 million topped Wall Street estimates of $151.8 million, reinforcing that demand remains solid. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company lifted FY2026 EPS guidance to $0.24-$0.32, well above the prior consensus, and revenue guidance of $602 million-$610 million is also near or slightly above expectations. AtriCure Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management described the quarter as one of “healthy growth” and a “significant step up in profitability,” which supports the recent stock strength. AtriCure Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Short-interest data showed 0 reported shares, so it does not appear to be a meaningful trading catalyst.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ATRC shares. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Tuesday. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Weiss Ratings lowered shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 4th. Finally, Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.12.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.